natgillin/translations-raw huggingface dataset:
ChondroCelect må ikke anvendes hos patienter, som er overfølsomme (allergiske) over for andre af indholdsstofferne eller over for bovint serum (blod fra kvæg).
ChondroCelect must not be used in people who are hypersensitive (allergic) to any of the other ingredients or to bovine serum (cow’s blood).
ChondroCelects karakter og dets tilsigtede kliniske anvendelse gør, at konventionelle undersøgelser af farmakokinetik, absorption, distribution, metabolisme og elimination ikke er relevante.
The nature and intended clinical use of ChondroCelect are such that conventional studies on pharmacokinetics, absorption, distribution, metabolism and elimination are not applicable.
Chorea (bevægelsesforstyrrelse), myoclonia (muskelspasme eller muskeltrækninger)
Chorea (movement disorder), myoclonia (muscle spasm or twitching)
Choriongonadotropin alfa
Choriogonadotropin alfa
Choriongonadotropin alfa ligner det hormon kaldet ’choriongonadotropin’, der findes naturligt i din krop, som er involveret i reproduktion og frugtbarhed.
Choriogonadotropin alfa is similar to a hormone found naturally in your body called ‘chorionic gonadotropin’, which is involved in reproduction and fertility.
Choriongonadotropin alfa.
Choriogonadotropin alfa.
Choriongonadotropin binder til ovarielle theca- (og granulosa-) celler til en transmembran-receptor, der deles med det luteiniserende hormon, LH/CG-receptoren.
Chorionic gonadotropin binds on the ovarian theca (and granulosa) cells to a transmembrane receptor shared with the luteinising hormone, the LH/CG receptor.
Choroidealøsning
Choroidal detachment
CHR (95% KI)
CHR (95% CI)
CHR: ANC 1,5 x 109/l, trombocytter 100 x 109/l, ingen blaster i blodet, BM-blaster < 5 % og ingen ekstramedullær sygdom].
CHR: ANC > 1.5 x 109/l, platelets >100x109/l, no blood blasts, BM blasts <5% and no extramedullary disease
CHR: I undersøgelse 0102 [ANC 1,5 x 109/l, trombocytter  100 x 109/l, ingen blaster i blodet, BM- blaster <5 % og ingen ekstramedullær sygdom].
In study 0102 [ANC ≥ 1.5 x 109/l, platelets ≥ 100 x 109/l, no blood blasts, BM blasts < 5 % and no extramedullary disease]
CHR: Undersøgelse 0110 [leukocytter <10 x 109/l, trombocytter <450 x 109/l, myelocyt+metamyelocyt <5% i blodet, ingen blaster eller promyelocytter i blodet, basophiler <20%, ingen ekstramedullær involvering] og i undersøgelse 0102 og 0109 [ANC ≥1,5 x 109/l, trombocytter ≥100 x 109/l, ingen blaster i blodet, BM-blaster <5% og ingen ekstramedullær sygdom]
CHR: Study 0110 [WBC < 10 x 109/l, platelets < 450 x 109/l, myelocyte+metamyelocyte < 5% in blood, no blasts and promyelocytes in blood, basophils < 20%, no extramedullary involvement] and in studies 0102 and 0109 [ANC ≥ 1.5 x 109/l, platelets ≥ 100 x 109/l, no blood blasts, BM blasts < 5% and no extramedullary disease]
CHR: WBC ≤ institutionel ULN, ANC ≥ 1.000/mm3, trombocytter ≥ 100.000/mm3, ingen blaster eller promyelocytter i perifert blod, knoglemarvsblaster ≤ 5% myelocytter plus metamyelocytter i perifert blod, basofilocytter i perifert blod < 20% og ingen ekstramedullær involvering.
CHR: WBC ≤ institutional ULN, ANC ≥ 1,000/mm3, platelets ≥ 100,000/mm3, no blasts or promyelocytes in peripheral blood, bone marrow blasts ≤ 5%, < 5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood < 20%, and no extramedullary involvement.
chromatopsia, cyanopsia, øjenirritation, okulær
Not known photophobia, chromatopsia, cyanopsia, eye irritation, ocular hyperaemia visual acuity reduced, diplopia, abnormal sensation in eye
chromoblastermykose og mycetom (langvarige svampeinfektioner i huden eller i vævet lige under huden, sædvanligvis forårsaget af svampesporer, der inficerer sår efter torne eller splinter) coccidioidomykose (svampeinfektion i lungerne opstået ved indånding af sporer).
chromoblastomycosis and mycetoma (long-term fungal infections of the skin or the tissue just below the skin, usually caused by fungal spores infecting wounds due to thorns or splinters), coccidioidomycosis (fungal infection of the lungs caused by breathing in spores).
chromoblastermykose og mycetom (langvarige svampeinfektioner i huden eller i vævet lige under huden, sædvanligvis forårsaget af svampesporer, der inficerer sår fra torne eller splinter), coccidioidomykose (svampeinfektion i lungerne, opstået ved indånding af sporer).
chromoblastomycosis and mycetoma (long-term fungal infections of the skin or the tissue just below the skin, usually caused by fungal spores infecting wounds due to thorns or splinters), coccidioidomycosis (fungal infection of the lungs caused by breathing in spores).
Chromoblastomykose og mycetoma hos patienter med sygdom, hvor behandling med itraconazol har været utilstrækkelig, eller hos patienter med intolerans over for itraconazol;
Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;
Churg-Strauss og hypereosinofilt syndrom er blevet set hos allergisk astma-patienter i behandling med Xolair.
Churg-Strauss and Hypereosinophilic syndrome have been observed in allergic asthma patients treated with Xolair.
Churg-Strauss og hypereosinofilt syndrom er blevet set hos patienter i behandling med Xolair.
Churg-Strauss and Hypereosinophilic syndrome have been observed in patients treated with Xolair.
Churg-Strauss syndrom og hypereosinofilt syndrom
Churg-Strauss syndrome and hypereosinophilic syndrome
Churg-Strauss-syndrom)
Churg-Strauss syndrome)
CHVP-IFN,
CHVP-IFN, 183
CI
75.0
CI 96,5 %
96.5% CI
CI = confidence interval, konfidensinterval, CTX = platinbaseret kemoterapi, ORR = objektiv responsrate, OS = overlevelsestid, PFS = progressionsfri overlevelsestid
CI = confidence interval, CTX = platinum-based chemotherapy, ORR = objective response rate, OS = overall survival time, PFS = progression-free survival time
CI = confidence interval, konfidensinterval, FOLFIRI = irinotecan plus 5-FU/FA-infusion, ORR = objective response rate (patienter med komplet respons eller delvis respons), OS = overlevelsestid, PFS = progressionsfri overlevelsestid
CI = confidence interval, FOLFIRI = irinotecan plus infusional 5-FU/FA, ORR = objective response rate (patients with complete response or partial response), OS = overall survival time, PFS = progression-free survival time
CI = confidence interval, konfidensinterval, FOLFOX4 = oxaliplatin plus kontinuerlig 5-FU/FA-infusion, ORR = objective response rate (patienter med komplet respons eller delvis respons), OS = overlevelsestid, PFS = progressionsfri overlevelsestid, NE = kan ikke estimeres
CI = confidence interval, FOLFOX4 = oxaliplatin plus continuous infusional 5-FU/FA, ORR = objective response rate (patients with complete response or partial response), OS = overall survival time, PFS = progression-free survival time, NE = not estimable
CI = konfidens interval (1) 3 vaccinedoser, DNA-negative og seronegative ved måned 0 og DNA-negative ved måned 6 for de relevante HPV-typer (HPV-16 og/eller HPV-18) (2) mindst en vaccinedosis, uanset HPV-DNA og serologisk status ved måned 0.
CI = Confidence Interval (1) 3 doses of vaccine, DNA negative and seronegative at month 0 and DNA negative at month 6 for the relevant HPV type (HPV-16 and/or HPV-18) (2) at least one dose of vaccine, irrespective of HPV DNA and serostatus at month 0.
CI = konfidensinterval, CRR = rate for fuldstændigt respons, CR= fuldstændigt respons, CRu = fuldstændigt respons ikke bekræftet, DMC =Data Monitoring Committee, ITT = intention-to-treat, HR = hazard ratio, KM = Kaplan-Meier, MIPI = Mantle Cell Lymphoma International Prognostic Index, NA = ikke relevant, ORR = samlet responsrate, PD= progressiv sygdom,
CI = confidence interval; CRR = complete response rate; CR = complete response; CRu = complete response unconfirmed; DMC = Data Monitoring Committee; ITT = intent-to-treat; HR = hazard ratio;
CI = konfidensinterval, CSF = cerebrospinalvæske, MRD = minimal residualsygdom a Ubetinget nøjagtigt konfidensinterval baseret på Chan og Zhang b Ubetinget nøjagtig test af non-inferioritet for binomiale forskelle baseret på estimater af begrænset maksimal sandsynlighed c Patienter blev anset for at respondere, hvis asparaginværdier i CSF på protokoldag 33 var under den nedre kvantificeringsgrænse.
CI = confidence interval; CSF = cerebrospinal fluid; MRD = minimal residual disease a Unconditional exact confidence interval based on Chan and Zhang b Unconditional exact test of non-inferiority for binomial differences based on restricted maximum likelihood estimates c Patients were considered as responders if asparagine values in CSF on protocol day 33 were below the lower limit of quantification.
CI = konfidensinterval, FEV1 = forceret ekspiratorisk volumen i 1 sekund, ITT = intent-to-treat (alle randomiserede patienter), P = P-værdi, SD = standardafvigelse, SE = standardfejl, ANCOVA = analyse af kovarians. a ANCOVA med betingelser for behandling, område, alder (16 til 18 år, > 18 år) og forventet baseline-FEV1- procent som kvartiler. (Bemærk: I studie 204 blev yderligere 38 patienter randomiseret til Quinsair 120 mg en gang dagligt (≥ 18 år, n = 35 og ≥ 16 til < 18 år, n = 3), og yderligere 37 patienter blev randomiseret til Quinsair 240 mg en gang daglig (≥ 18 år, n = 34 og ≥ 16 til < 18 år, n = 3). b LS-middelværdiforskel for Quinsair minus placebo. c Testet ved anvendelse af alfa på 0,05.
CI = Confidence interval; FEV1 = forced expiratory volume in 1 second; ITT = intent to treat (all patients randomised); P = P value; SD = standard deviation; SE = standard error; ANCOVA = analysis of covariance. a ANCOVA with terms for treatment, region, age (16 to 18 years, > 18 years), and baseline FEV1 percent predicted as quartiles. (Note: In Study 204, an additional 38 patients were randomised to Quinsair 120 mg once daily (≥ 18 years, n = 35; ≥ 16 to < 18 years old, n = 3) and an additional 37patients were randomised to Quinsair 240 mg once daily (≥ 18 years, n = 34; ≥ 16 to < 18 years old, n = 3).) b LS Mean difference for Quinsair minus placebo. c Tested using alpha of 0.05.
CI = konfidensinterval, FEV1 = forceret ekspiratorisk volumen i 1 sekund, ITT = intent-to-treat (alle randomiserede patienter), P = P-værdi, SD = standardafvigelse, SE = standardfejl, TIS = tobramycin- inhalationsopløsning.
CI = Confidence interval; FEV1 = forced expiratory volume in 1 second; ITT = intent-to-treat (all patients randomised); P = P-value; SD = standard deviation; SE = standard error; TIS = tobramycin inhalation solution.
CI = konfidensinterval, HRA+G/G = hazard ratio for Abraxane+gemcitabin/gemcitabin, pA+G/pG=responsrate -forhold af Abraxane+gemcitabin/gemcitabin a stratificeret Cox proportionel hazard-model b stratificeret log-rank-test, stratificeret ved geografisk region (Nordamerika versus andre), KPS (70 til 80 versus 90 til 100) og tilstedeværelse af levermetastase (ja versus nej).
CI = confidence interval, HRA+G/G = hazard ratio of Abraxane+gemcitabine/gemcitabine, pA+G/pG=response rate ratio of Abraxane+gemcitabine/gemcitabine a stratified Cox proportional hazard model b stratified log-rank test, stratified by geographic region (North America versus others), KPS (70 to 80 versus 90 to 100), and presence of liver metastasis (yes versus no).
CI = konfidensinterval, HRA/T = Hazard ratio af Abraxane/carboplatin i forhold til solvensbaseret paclitaxel/carboplatin, pA/pT = responsrate for Abraxane/carboplatin i forhold til solvensbaseret paclitaxel/carboplatin. a P-værdien er baseret på en chi2-test.
CI = confidence interval; HRA/T = hazard ratio of Abraxane/carboplatin to solvent-based paclitaxel/carboplatin; pA/pT = response rate ratio of Abraxane/carboplatin to solvent-based paclitaxel/carboplatin. a P-value is based on a chi-square test.
CI = konfidensinterval, HRA/T = Hazard ratio af Abraxane/carboplatin til solvensbaseret paclitaxel/carboplatin, pA/pT = responsrate for Abraxane/carboplatin i forhold til solvensbaseret paclitaxel/carboplatin. a I henhold til metodologiske overvejelser fra EMA for PFS-endepunkt blev manglende observationer eller påbegyndelse af efterfølgende nye behandlinger ikke anvendt til censurering.
CI = confidence interval; HRA/T = hazard ratio of Abraxane/carboplatin to solvent-based paclitaxel/carboplatin; pA/pT = response rate ratio of Abraxane/carboplatin to solvent-based paclitaxel/carboplatin. a Per EMA methodological considerations for PFS endpoint, missing observations or initiation of subsequent new therapy were not used for censoring.
CI = konfidensinterval, LS-gennemsnit = gennemsnit beregnet efter mindste kvadraters metode (least square mean), N = antal uden manglende værdier, OPC = opicapon. a.
CI = confidence interval; LS mean = least square mean; N = number of non-missing values; OPC = opicapone. a.
CI = konfidensinterval, NE = kunne ikke estimeres aPoint-estimater er baseret på Kaplan-Meier-metoden, og 95 % CI er baseret på Greenwood-formlen ved brug af log-log-transformation. bStratificeret hazard ratio er baseret på en stratificeret Cox-regressionsmodel, som inkluderer behandling som en kovariat og hæmoglobin og korrigeret serum-calcium som strata.
CI = confidence interval, NE = not estimable aPoint estimates are based on Kaplan-Meier method and 95% CIs are based on the Greenwood formula using log-log transformation. bStratified hazard ratio is based on a stratified Cox regression model including treatment as a covariate factor and hemoglobin and corrected serum calcium as strata.
CI = konfidensinterval.
CI = confidence interval
CI = konfidensinterval; CR = komplet respons; nCR = næsten komplet respons; ITT = intent to treat; RR = responsrate; Vc = VELCADE; VcDx = VELCADE, dexamethason; VDDx = vincristin, doxorubicin, dexamethason; VGPR = virkeligt godt partielt respons; PR = partielt respons; OR = odds ratio;
CI=confidence interval; CR=complete response; nCR=near complete response; ITT=intent to treat; RR=response rate; Vc=VELCADE; VcDx=VELCADE, dexamethasone; VDDx=vincristine, doxorubicin, dexamethasone; VGPR=very good partial response; PR=partial response; OR=odds ratio.
CI = konfidensinterval; CR = komplet respons; nCR = næsten komplet respons; ITT = intent to treat; RR = responsrate; Vc = VELCADE; VcTDx = VELCADE, thalidomid, dexamethason; TDx = thalidomid, dexamethason; tttPR = partielt respons; OR = odds-ratio;
CI=confidence interval; CR=complete response; nCR=near complete response; ITT=intent to treat; RR=response rate; Vc=VELCADE; VcTDx=VELCADE, thalidomide, dexamethasone; TDx=thalidomide, dexamethasone; PR=partial response; OR=odds ratio
CI = konfidensinterval; CR = komplet respons; PR = partielt respons; NR = ikke nået
CI = confidence interval; CR = complete response; PR = partial response; NR = not reached
CI = konfidensinterval; EOT =behandlingsafslutning; HR = risikoforhold; i.v. = intravenøs; PAH = pulmonal arteriel hypertension; s.c. = subkutan.
CI = confidence interval; EOT = end of treatment; HR = hazard ratio; i.v. = intravenous; PAH = pulmonary arterial hypertension; s.c. = subcutaneous.
CI = Konfidensinterval; ER = østrogenreceptor PR = progesteronreceptor a ER/PR-negativ eller grad 3 eller tumorstørrelse >5 cm
PR = progesterone receptor a ER/PR-negative or Grade 3 or tumor size >5 cm
CI = Konfidensinterval; ER = østrogenreceptor PR = progesteronreceptor a ER/PR-negativ eller grad 3 eller tumorstørrelse >5 cm
PR = progesterone receptor aER/PR-negative or Grade 3 or tumor size >5 cm
CI = konfidensinterval; NR = ikke nået; MR = mindre respons; PR = partielt respons; VGPR = meget godt partielt respons; ORR = MR+PR+VGPR
CI = confidence interval; NR = not reached; MR = minor response; PR = partial response; VGPR = very good partial response; ORR = MR+PR+VGPR
CI = sikkerhedsinterval; NA = ikke relevant. a Baseret på log-rank test stratificeret på tidligere nephrectomistatus og region. b Baseret på Cox proportional risikomodel stratificeret på tidligere nephrectomistatus og region. c Baseret på Cochran-Mantel-Haenszel test stratificeret på tidligere nephrectomistatus og region.
CI = confidence interval; NA = not applicable. a Based on log-rank test stratified by prior nephrectomy and region. b Based on Cox proportional hazard model stratified by prior nephrectomy and region (95% CI are descriptive only). c Based on Cochran-Mantel-Hansel test stratified by prior nephrectomy and region.
CI Konfidensinterval
CI Confidence Interval
CI95%, 0,93%, 7,97%
CI95% 0.93%, 7.97
CI95%, 0,93%; 7,97%
CI95% 0.93%, 7.97
CI95%, 45 min, 1 t 56 min
CI95% 45 min, 1 h 56 min
CI95%, 45 min,1 t 56 min
CI95% 45 min, 1 h 56
CI: 14,2 % - 45,2 %] CRh*).
14.2% - 45.2%] CRh*).
CI: 8,0-35,2 %) og 0 (0 %; 95 % CI: 0,0-9,7 %).
0.0-9.7%), respectively.
CI: konfidensinterval, n: antalpatienter, der responderer
CI: confidence interval; n: number of responding subjects
CI: konfidensinterval, NA: ikke analyseret på grund af en lav forekomst af hændelserne a Behandlingsforskel = virkning af ivacaftor – virkning af placebo b CFQ-R: Cystic Fibrosis Questionnaire-Revised er et sygdomsspecifikt, sundhedsrelateret mål for livskvalitet for CF.
CI: confidence interval; NA: not analysed due to low incidence of events a Treatment difference = effect of ivacaftor – effect of placebo
CI: konfidensinterval; O: ofatumumab; N: antalpatienter pr. gruppe
CI: confidence interval; O: ofatumumab; N: number of subjects per group
CI: konfidensinterval; O: ofatumumab; n: antalpatienter, der responderer; N: antalpatienter igruppen; NR: ikke nået (notreached).
CI: confidence interval; O: ofatumumab; n: number of responding subjects; N: number of subjects per group; NR: not reached.
CI: konfidensinterval; R: rituximab; N: antalpatienter pr. gruppe; NR: ikke nået (not reached)
CI: confidence interval; R: rituximab; N: number of subjects per group; NR: not reached
CI: konfidensinterval; R: rituximab; n: antalpatienter, der responderer; N: antalpatienter igruppen; NR: ikke nået (notreached).
CI: confidence interval; R: rituximab; n: number of responding subjects; N: number of subjects per group; NR: not reached.
CI=Konfidensinterval, HR=hazard ratio, NA=Ikke relevant
CI=Confidence interval, HR=Hazard ratio, NA=Not applicable
CI=konfidensinterval; CR=komplet respons; nCR=næsten komplet respons; ITT=intent to treat; RR=responsrate; Bz= bortezomib; BzDx= bortezomib, dexamethason; VDDx=vincristin, doxorubicin, dexamethason; VGPR=virkeligt godt partielt respons; PR=partielt respons; OR=odds ratio;
CI=confidence interval; CR=complete response; nCR=near complete response; ITT=intent to treat; RR=response rate; Bz= bortezomib; BzDx= bortezomib, dexamethasone; VDDx=vincristine, doxorubicin, dexamethasone; VGPR=very good partial response; PR=partial response; OR=odds ratio.
CI=konfidensinterval; CR=komplet respons; nCR=næsten komplet respons; ITT=intent to treat; RR=responsrate; Bz= bortezomib; BzTDx= bortezomib, thalidomid, dexamethason; TDx=thalidomid, dexamethason; tttPR=partielt respons; OR=odds-ratio;
CI=confidence interval; CR=complete response; nCR=near complete response; ITT=intent to treat; RR=response rate; Bz= bortezomib; BzTDx= bortezomib, thalidomide, dexamethasone; TDx=thalidomide, dexamethasone; PR=partial response; OR=odds ratio
CI=konfidensinterval; CR=komplet respons; nCR=næsten komplet respons; ITT=intent to treat; RR=responsrate; Bzmb=bortezomib; BzmbDx=bortezomib, dexamethason; VDDx=vincristin, doxorubicin, dexamethason; VGPR=virkeligt godt partielt respons; PR=partielt respons; OR=oddsratio.
CI=confidence interval; CR=complete response; nCR=near complete response; ITT=intent to treat; RR=response rate; Bzmb=bortezomib; BzmbTDx=bortezomib, thalidomide, dexamethasone; TDx=thalidomide, dexamethasone; PR=partial response;
CIALIS 10 mg er lysegule filmovertrukne tabletter (tablet), der har mandelform og er mærket med ”C 10” på den ene side.
CIALIS 10 mg is a light yellow film-coated tablet in the shape of an almond and has "C 10" marked on one side.
CIALIS 10 mg filmovertrukne tabletter Hver tablet indeholder 10 mg tadalafil.
CIALIS 10 mg film-coated tablets Each tablet contains 10 mg tadalafil.
CIALIS 10 mg filmovertrukne tabletter tadalafil
CIALIS 10 mg film-coated tablets tadalafil
CIALIS 10 mg tabletter tadalafil
CIALIS 10 mg tablets tadalafil
CIALIS 2,5 mg filmovertrukne tabletter
CIALIS 2.5 mg film-coated tablets
CIALIS 2,5 mg filmovertrukne tabletter tadalafil
CIALIS 2.5 mg film-coated tablets tadalafil
CIALIS 2,5 mg filmovertrukne tabletter.
CIALIS 2.5 mg film-coated tablets
CIALIS 2,5 mg tabletter tadalafil
CIALIS 2.5 mg tablets tadalafil
CIALIS 20 mg er gule filmovertrukne tabletter, der har mandelform og er mærket med ”C 20” på den ene side.
CIALIS 20 mg is a yellow film-coated tablet in the shape of an almond and has "C 20" marked on one side.
CIALIS 20 mg filmovertrukne tabletter tadalafil
CIALIS 20 mg film-coated tablets tadalafil
CIALIS 20 mg tabletter tadalafil
CIALIS 20 mg tablets tadalafil
CIALIS 5 mg bruges til at behandle voksne mænd for:
CIALIS 5 mg is used to treat adult men with:
CIALIS 5 mg er lysegule filmovertrukne tabletter, der har mandelform og er mærket med ”C 5” på den ene side.
CIALIS 5 mg is a light yellow film-coated tablet in the shape of an almond and has "C 5" marked on one side.
CIALIS 5 mg filmovertrukne tabletter
CIALIS 5 mg film-coated tablets
CIALIS 5 mg filmovertrukne tabletter tadalafil
CIALIS 5 mg film-coated tablets tadalafil
CIALIS 5 mg filmovertrukne tabletter.
CIALIS 5 mg film-coated tablets
CIALIS 5 mg tabletter tadalafil
CIALIS 5 mg tablets tadalafil
Cialis blev undersøgt i seks hovedundersøgelser, der omfattede 1 328 patienter med erektil dysfunktion, hvor det blev indtaget efter behov inden seksuel aktivitet.
Cialis, when taken ‘on demand’ before sexual activity, has been studied in six main studies including 1,328 patients with erectile dysfunction.
CIALIS bør ikke anvendes til patienter med arvelig galactoseintolerans, en særlig form af hereditær lactasemangel (Lapp Lactase deficiency) eller glucose/galactose- malabsorption.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
CIALIS er ikke beregnet til børn og unge under 18 år.
CIALIS is not intended for use by children and adolescents under the age of 18.
CIALIS er tilgængeligt i tabletstyrker på 2,5, 5, 10 og 20 mg til oral brug
CIALIS is available as 2.5, 5, 10, and 20 mg film-coated tablets for oral use.
CIALIS er tilgængeligt i tabletstyrker på 2,5, 5, 10 og 20 mg til oral brug.
CIALIS is available as 2.5, 5, 10, and 20 mg film-coated tablets for oral use.
CIALIS indeholder lactose:
CIALIS contains lactose:
Cialis kan, med udgangspunkt i lægens vurdering, indtages ved en lavere dosis én gang dagligt af mænd, som ønsker at bruge lægemidlet ofte (to gange om ugen eller mere).
Cialis can be used at a lower dose once a day in men who intend to use it frequently (twice a week or more), based on the doctor’s judgement.
Cialis må ikke tages sammen med nitrater (en gruppe af lægemidler der anvendes til behandling af angina) eller lægemidler i klassen "guanylatcyklase-stimulatorer", såsom riociguat (et lægemiddel til behandling af højt blodtryk i de kar, der forsyner lungerne, kendt som pulmonal hypertension).
Cialis must not be taken with nitrates (a type of medicine used for angina) or medicines of the class ‘guanylate cyclase stimulators’ such as riociguat (a medicine for high blood pressure in the vessels supplying the lungs, known as pulmonary hypertension).
CIALIS og andre behandlinger for erektil dysfunktion
CIALIS and other treatments for erectile dysfunction
cialis10 mg
cialis 10 mg
CIAMBRA 100 mg pulver til koncentrat til infusionsvæske, opløsning.
CIAMBRA 100 mg powder for concentrate for solution for infusion
CIAMBRA 100 mg pulver til koncentrat til infusionsvæske, opløsning. pemetrexed
CIAMBRA 100 mg powder for concentrate for solution for infusion Pemetrexed
CIAMBRA 500 mg pulver til koncentrat til infusionsvæske, opløsning.
CIAMBRA 500 mg powder for concentrate for solution for infusion
CIAMBRA 500 mg pulver til koncentrat til infusionsvæske, opløsning. pemetrexed
CIAMBRA 500 mg powder for concentrate for solution for infusion Pemetrexed
Ciambra er et "generisk lægemiddel".
Ciambra is a ‘generic medicine’.